The Serum Institute of India have given the first formal application for emergency use approval for AstraZeneca Plc’s COVID-19 vaccine. Serum Institute is India is main hope of large-scale supplies of COVID vaccine in India.
Competitor Pfizer and Moderna Incorporation also applied for emergency use approval for COVID vaccine. AstraZeneca’s vaccine, called “Covishield” by Serum Institute, can be stored at two to eight degrees Celsius and distributed more easily in India.